| Symbol
| KDM4B
| contributors: mct - updated : 23-12-2020
|
| HGNC name
| lysine (K)-specific demethylase 4B
|
| HGNC id
| 29136
|
| corresponding disease(s)
|
GDDLM
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
|
in renal cancer cells that have lost the von Hippel Lindau tumor suppressor protein VHL and therefore display a deregulated expression of hypoxia-inducible factor  | | tumoral
|
|
| --over
|
| |
in colorectal cancer (CRC) tissues | |
Variant & Polymorphism
| 
| |
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | reproductive | prostate | |
| is a viable therapeutic target in Prostate carcinoma | | cancer | reproductive | breast | |
| potential therapeutic target in breast cancer | | cancer | reproductive | prostate | |
| KDM4B may be served as a potential target for Castration-resistant prostate cancer (CRPC) therapy | | cancer | digestive | colon | |
| potential therapeutic cancer target in Colorectal cancer ( | | osteoarticular | bone | ostéoporosis | |
| KDM4B may present as therapeutic targets for controlling mesenchymal stem/stromal cells (MSCs) fate choices and lead to clues for new treatment in metabolic bone diseases such as osteoporosis |
| | | |